Impact of a real-time targeted expert outreach model on conversion of biomarker results to precision treatments.

Abstract

e23390 Background: Previous publications reported low rates of converting positive biomarker results into appropriate treatments as a reason for precision oncology practice gaps. One key cause being awareness: physicians are inundated with the rapidly evolving treatment landscapes and struggle to recall clinical utility for rare or emerging biomarkers. Proactive engagement efforts to educate physicians on biomarker-dependent treatments can help alleviate this gap. Pathologists, key experts in biomarker testing/reporting, are ideally positioned to lead such initiatives. We therefore hypothesize that real-time, targeted outreach to physicians from pathologists following positive biomarker tests will help support timely and appropriate precision therapy delivery. The aim of this study is to evaluate the impact of this real-time expert outreach model in boosting awareness of the clinical utility of novel or rare biomarkers in solid tumors. Methods: Real-world data from unstructured testing reports were collected from > 500 laboratories across the US in 2025. Diaceutics proprietary Agentic Artificial Intelligence platform was applied to identify HIPAA-compliant positive cases for selected novel and rare actionable biomarkers (1-2% incidence rate in solid tumors). Physicians associated with these cases were identified as candidates for engagement by expert pathologists who performed timely review of case details ahead of the outreach and provided targeted awareness on the clinical utility of positive biomarker results. Results: Among 34,242 solid tumor patients who underwent biomarker testing in 2025, 67 anonymized patients potentially eligible for a novel precision therapy based on positive rare biomarker fusion, were found. Based on this data, physicians who ordered these tests were identified, and were later matched with a pathologist for an outreach awareness program. Connections between pathologists and physicians were successfully established for 37 outreaches (55%), whilst 14 (21%) are still ongoing and 16 were declared to be unsuccessful (24%). Among those successfully connected physicians, only 15% reported being fully aware of the biomarker’s clinical utility, whereas 85% had limited or no awareness. This lack of awareness poses a risk on many patients missing appropriate biomarker-directed treatments. Through the pathologists-led discussion, this expert outreach program enabled 23/37 patients (62%) to receive treatment aligned with their molecular profile, who might have otherwise be missed in precision oncology practice. Conclusions: Our preliminary data confirms this real-time targeted expert (pathologists) outreach after rare actionable biomarker detection was feasible and substantially supported fostering awareness on clinical utility of novel or rare biomarkers to physicians for delivering timely and appropriate precision therapy.